On one of its first studies looking at the effects of intranasal-delivered POH as a therapeutic for cancer, NeOnc Technologies Holdings, Inc. demonstrated that its NEO100 formulation had a marked therapeutic effect on patients with recurrent gliomas. The patients that were studied had become unresponsive to standard cancer therapeutic regimens and faced a dismal prognosis. […]